Skip Navigation



NDT Advance Access published online on February 3, 2007
Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfl793
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
22/5/1338    most recent
gfl793v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Wilson, J. C.
Right arrow Articles by Eccles, M. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wilson, J. C.
Right arrow Articles by Eccles, M. R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2007]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

A novel Cys1638Tyr NC1 domain substitution in {alpha}5(IV) collagen causes Alport syndrome with late onset renal failure without hearing loss or eye abnormalities

Jane C. Wilson1, Han-Seung Yoon1, Robert J. Walker2 and Michael R. Eccles1

1Department of Pathology and 2Department of Medical and Surgical Sciences, University of Otago, P.O. Box 913, Dunedin, New Zealand

Correspondence and offprint requests to: Michael Eccles, Department of Pathology, University of Otago, P.O. Box 913, Dunedin, New Zealand. Email: michael.eccles{at}stonebow.otago.ac.nz



  Abstract

Background. Mutations in the type IV collagen gene, COL4A5, are associated with Alport syndrome, characterized by ultrastructural abnormalities of the glomerular basement membrane (GBM), with or without progressive loss of renal function, characteristic ophthalmic signs and/or high tone sensorineural deafness. More than 300 sequence variants in type IV collagen have been identified, including alterations in the non-collagenous NC1 domain.

Methods. We performed linkage analysis and sequencing to identify the mutation in a New Zealand family with Alport glomerulonephritis and late onset renal failure without hearing loss or eye abnormalities.

Results. We report a novel c.4913G>A (p.Cys1638Tyr) alteration in the NC1 domain of COL4A5, identified in a moderately large family, eight of whom were confirmed by renal biopsy to have renal abnormalities. Only three of eight mutant male members of the pedigree progressed to end-stage renal failure. The remaining five mutant males exhibit either chronic renal disease at age 36, 46 and 72, or as yet show no renal disease at ages 39 and 39. Extra-renal manifestations such as sensorineural deafness or ocular changes were absent from all family members carrying the mutation.

Conclusion. This variant is the first reported to affect the tenth of 12 cysteine residues in the NC1 domain. We conclude that the cysteine to tyrosine substitution in the NC1 domain of the {alpha}5(IV) collagen chain in this family leads to a mild form of Alport syndrome, including absence of extra-renal features.

Keywords: alport syndrome; COL4A5; mild phenotype; mutation analysis


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.